View in EDS

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.

Saved in:
Bibliographic Details
Title: Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Authors: Gan HK; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia., Parakh S; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Monash Health, Clayton, Melbourne, Australia., Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, NY, USA., Seow A; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Lau E; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia., Lee ST; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Ameratunga M; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia., Perchyonok Y; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia., Cao D; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia., Burvenich IJG; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia., O'Keefe GJ; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Rigopoulos A; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia., Gomez E; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA., Maag D; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA., Scott AM; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.
Source: Neuro-oncology advances [Neurooncol Adv] 2021 Aug 03; Vol. 3 (1), pp. vdab102. Date of Electronic Publication: 2021 Aug 03 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34549181
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gan+HK%22">Gan HK</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.<br /><searchLink fieldCode="AU" term="%22Parakh+S%22">Parakh S</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Monash Health, Clayton, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Lassman+AB%22">Lassman AB</searchLink>; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Seow+A%22">Seow A</searchLink>; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Lau+E%22">Lau E</searchLink>; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Lee+ST%22">Lee ST</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Ameratunga+M%22">Ameratunga M</searchLink>; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Perchyonok+Y%22">Perchyonok Y</searchLink>; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Cao+D%22">Cao D</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Burvenich+IJG%22">Burvenich IJG</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22O'Keefe+GJ%22">O'Keefe GJ</searchLink>; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Rigopoulos+A%22">Rigopoulos A</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Gomez+E%22">Gomez E</searchLink>; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Maag+D%22">Maag D</searchLink>; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Scott+AM%22">Scott AM</searchLink>; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101755003%22">Neuro-oncology advances</searchLink> [Neurooncol Adv] 2021 Aug 03; Vol. 3 (1), pp. vdab102. <i>Date of Electronic Publication: </i>2021 Aug 03 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755003 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-2498 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226322498%22">26322498 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34549181
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/noajnl/vdab102
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: vdab102
    Titles:
      – TitleFull: Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gan HK
      – PersonEntity:
          Name:
            NameFull: Parakh S
      – PersonEntity:
          Name:
            NameFull: Lassman AB
      – PersonEntity:
          Name:
            NameFull: Seow A
      – PersonEntity:
          Name:
            NameFull: Lau E
      – PersonEntity:
          Name:
            NameFull: Lee ST
      – PersonEntity:
          Name:
            NameFull: Ameratunga M
      – PersonEntity:
          Name:
            NameFull: Perchyonok Y
      – PersonEntity:
          Name:
            NameFull: Cao D
      – PersonEntity:
          Name:
            NameFull: Burvenich IJG
      – PersonEntity:
          Name:
            NameFull: O'Keefe GJ
      – PersonEntity:
          Name:
            NameFull: Rigopoulos A
      – PersonEntity:
          Name:
            NameFull: Gomez E
      – PersonEntity:
          Name:
            NameFull: Maag D
      – PersonEntity:
          Name:
            NameFull: Scott AM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 08
              Text: 2021 Aug 03
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2632-2498
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Neuro-oncology advances
              Type: main
ResultId 1